China: Data Protection

China's revised Good Clinical Practice for Drug Trials took effect on 1 September 2026, fundamentally reshaping the regulatory landscape for clinical trials by aligning domestic requirements with ICH E6(R3) standards. The new framework introduces streamlined regulations spanning just 54 articles across six chapters, while establishing comprehensive data governance requirements and clarifying ultimate accountability for sponsors, principal investigators, and clinical trial institutions. Companies conducting

China's Q2 2026 regulatory landscape saw major developments across data privacy, foreign investment, intellectual property, and international trade. New measures operationalize network data security risk assessments, establish comprehensive outbound investment rules, revise trademark law to combat squatting, and introduce supply chain security frameworks with anti-extraterritorial jurisdiction countermeasures.

China's Supreme People's Court has issued its first comprehensive judicial guidance on artificial intelligence disputes, establishing how existing intellectual property...

具身智能设备涉及机器人厂商、模型公司、云平台等多方协作,数据处理、模型调用和设备控制相互关联。企业如何在多主体生态中明确责任边界、

中国最高人民法院は9月7日、「AI関連紛争事件の法に基づく審理に関する最高人民法院の意見」を公表した。国の最高司法機関が人工知能関連の司法判断ルールを示す初の文書となる。

Cloud computing has evolved from basic infrastructure deployment into a sophisticated ecosystem encompassing IaaS, PaaS, SaaS, and emerging AI services. As China's cloud market reaches 828.8...

2026年6月18日，国家互联网信息办公室、工业和信息化部、公安部联合公布《网络数据安全风险评估办法》（以下简称“《办法》”），并将于2026年8月20日起施行。

北京仲裁委员会于2025年12月31日通过并自2026年1月1日起施行的《数字经济仲裁规则》...

The six-year protection applies to innovative drugs and originator drugs, calculated from the date of drug registration. Improved new drugs receive four years of data protection, and first generic drugs receive three years, according to a guideline issued by the administration. Ordinary generic drugs and biosimilars are not granted data protection.